US/UK/Canada

Share

Pick a time period -
Tags ( Active)

Photocure ASA to Acquire Vesica Health Inc., Strengthening Leadership in Bladder Cancer Diagnostics

Oslo, Norway – June 4, 2026 – Photocure ASA (OSE: PHO), a leader in bladder cancer diagnostics, today announced the signing and successful completion of its acquisition of Vesica Health, a U.S. established precision diagnostics company advancing AssureMDx, a urine-based molecular test for the early detection of bladder cancer, in a transaction designed to expand Photocure’s position across the bladder cancer care continuum.Transaction Highlights ·  USD 30.5M in total cash + stock transaction · Of which USD 3.0M equity investment made during Q1 2026. · Net consideration of

AUA 2026: new studies demonstrated Blue Light Cystoscopy benefits in high-risk NMIBC management and cost comparison study

Press Release – Oslo, Norway, May 18, 2026: Photocure ASA (OSE: PHO), the Bladder Cancer Company, announces the presentation of two Photocure-supported abstracts at the American Urological Association Annual Congress (AUA) 2026. The first highlighted the benefits of Blue Light Cystoscopy (BLC[®]), notably its diagnostic sensitivity impacting the management of high-risk NMIBC* patients, helping urologists and patients make well-informed decisions. The second abstract investigated the impact of avoiding recurrence in a Blue Light versus White Light Cystoscopy (WLC) comparison of costs at 5

Photocure ASA: Results for the first quarter of 2026

Oslo, Norway, 7 May 2026 - Photocure ASA (OSE:PHO) today reported Hexvix®/Cysview® revenues of NOK 139.0 million in the first quarter of 2026 (Q1 2025: NOK 125.3 million), and an adjusted EBITDA of NOK 15.3 million (Q1 2025: NOK 9.7 million) for the company. In 2026, Photocure expects product revenue growth in the range of 7% to 11% on a constant currency basis and adjusted EBITDA margin expansion.“Photocure delivered a solid start to 2026, with strong growth across all territories and continued execution across both our commercial and strategic priorities. Revenue growth was robust in

New health economic methodology published: comparing cost-effectiveness of BLC versus NBI imaging technology in bladder cancer

Press Release – Oslo, Norway, May 4, 2026: Photocure ASA (OSE: PHO), the Bladder Cancer Company, announces the publication in “The Journal of Medical Economics” of a novel health economics methodology used to develop the cost-utility model which compared blue light cystoscopy (BLC[®]) and Narrow Band Imaging (NBI), developed for a health technology appraisal by the Danish Treatment Council last year. The results of that analysis demonstrated that BLC is cost-effective versus NBI, when assessed over the remaining lifetime of the patient.The article “Addressing the challenges of health

Photocure ASA: Invitation to presentation of first quarter 2026 financial results

Oslo, Norway, 30 April 2026: Photocure ASA (Photocure, PHO: OSE) will announce the first quarter 2026 financial results on Thursday 7 May 2026 at 08:00 CEST and will present a live webcast at 14:00 CEST the same day.The quarterly report and presentation will be published at 08:00 CEST and will be publicly available at www.photocure.com.   The investor presentation will be streamed live and hosted by Dan Schneider, CEO and Erik Dahl, CFO. The presentation will be held in English and questions can be submitted throughout the event. The presentation is scheduled to conclude at 14:45 CEST.

Photocure ASA: Annual Report 2025

Oslo, Norway, 27 April 2026: Photocure ASA today announces the publication of the Annual Report and integrated ESG report for 2025.The Board of Directors of Photocure ASA has approved the annual accounts and remuneration report for 2025. The financial statements and annual report for the financial year 2025 are together with the ESG report and auditor's report attached to this notice. The ESEF file and remuneration report for 2025 are also attached. The documents are enclosed and also made available at the company's website under https://photocure.com/investors-hub/investors-events-and-

Photocure ASA: Update on milestone payments from Asieris Pharmaceuticals

Oslo, Norway, April 20, 2026 – Reference is made to Photocure ASA's (OSE: PHO) announcement dated 3 March 2026, in which the Company noted that its partner, Asieris Pharmaceuticals (SSE: 688176), had announced receipt of the Drug Registration Certificate from China's National Medical Products Administration (NMPA) for its core product APL-1702 (trade name: CEVIRA®). This approval enables commercial launch in China. Photocure further confirmed in this announcement that with Cevira’s regulatory approval in China it is entitled to a milestone payment.Photocure has in accordance with its

Photocure ASA: Update on Regulatory Classification for OAY Equipment

Oslo, Norway, April 13, 2026 — Photocure ASA (OSE: PHO) today announced that the U.S. Food and Drug Administration (FDA) has communicated to Photocure that it plans to issue a proposed order to reclassify diagnostic endoscopic light source systems (FDA Product Code OAY) under its own initiative per Section 513(f)(3) of the Federal Food, Drug, and Cosmetic Act.This information was shared with Photocure as part of its ongoing dialogue with the FDA, following the Reclassification Petition submitted by Karl Storz SE & Co. KG and addressed in Photocure’s press release of 28 March 2026.

Photocure: Trials in Progress presented at the European Association of Urology (EAU) 2026 congress aim to enable a more personalized bladder cancer care pathway

Press Release – Oslo, Norway, March 16, 2026: Photocure ASA (OSE: PHO), the Bladder Cancer Company, announces two “trial in progress” presentations at the 2026 European Association of Urology congress (EAU) in London, UK. These trials investigate different stages of the diagnostic pathway, addressing data gaps to improve individual patient care and outcomes.The EAU annual meeting is one of the largest international meetings in the global urology calendar, showcasing the latest and most relevant clinical and scientific advancements in this area of patient care.Photocure participated with

Asieris: CEVIRA Approved in China as First-in-Class Non-Invasive Therapy for Cervical Precancerous Lesions

Press release – Oslo, Norway, March 3, 2026: Photocure ASA (OSE: PHO), the Bladder Cancer Company, announces that its partner Asieris Pharmaceuticals (SSE: 688176) communicated today that its core product APL-1702 (trade name: CEVIRA[®]), has received the Drug Registration Certificate from China’s National Medical Products Administration (NMPA), enabling commercial launch in China.Cevira (APL-1702) is a photodynamic drug-device combination product in development for the non-surgical treatment of high-grade squamous intraepithelial lesions (HSIL), licensed to Asieris by Photocure. With

Photocure partner Asieris announces that EMA has accepted Marketing Authorization Application for CEVIRA in Europe

Press release – Oslo, Norway, February 27, 2026: Photocure ASA (OSE: PHO), the Bladder Cancer Company, announces that its partner Asieris Pharmaceuticals (SSE: 688176) communicated today that its marketing authorization application (MAA) for Cevira[®] (APL-1702) for the treatment of high-grade squamous intraepithelial lesions (HSIL) has been accepted by the European Medicines Agency (EMA).Asieris’ media release states about APL-1702, the first-in-class photodynamic therapy product: “As a drug-device combination, it integrates hexaminolevulinate hydrochloride ointment with a disposable

Photocure ASA: Results for the fourth quarter of 2025

Oslo, Norway, 18 February 2026 - Photocure ASA (OSE:PHO) today reported Hexvix®/Cysview® revenues of NOK 135.1 million in the fourth quarter of 2025 (Q4 2024: NOK 128.6 million), and a commercial EBITDA of NOK 8.4 million (Q4 2024: NOK 3.9 million) for the company. In 2026, Photocure expects product revenue growth in the range of 7% to 11% on a constant currency basis and continued operating leverage flow-through in its core Hexvix®/Cysview® commercial business.“Photocure delivered a strong fourth quarter, finishing the year at the top end of guidance on revenue. Operating leverage was

Photocure ASA: Invitation to presentation of 4th quarter and preliminary full year 2025 financial results

Oslo, Norway, 11 February 2026: Photocure ASA (Photocure, PHO: OSE) will announce the fourth quarter and preliminary full year 2025 financial results on Wednesday 18 February 2026 at 08:00 CET and will present a live webcast at 14:00 CET the same day.The quarterly report and presentation will be published at 07:00 CET and will be publicly available at www.photocure.com.   The investor presentation will be streamed live and hosted by Dan Schneider, CEO and Erik Dahl, CFO. The presentation will be held in English and questions can be submitted throughout the event. The presentation is

New publication of Hexvix trial data from China: blue light cystoscopy with Hexvix significantly improves the detection of bladder cancer using modern HD equipment

Press release – Oslo, Norway, January 12th, 2026: Photocure announces the publication of the study “Hexaminolevulinate blue light cystoscopy improves bladder cancer detection in comparison to white light cystoscopy: a prospective, comparative, within-patient controlled multicenter phase III bridging study in China” in the Frontiers of Urology journal this week.An abstract with data from this pivotal prospective randomized controlled multi-center Phase 3 trial was first presented at the Congress of the Société Internationale d’Urologie (SIU) in October 2023. Its main objective was to compare

The impact of avoiding recurrence: New BRAVO Study abstract at SUO 2025 demonstrates Cost Neutrality in Blue Light versus White Light Cystoscopy comparison

Press Release – Oslo, Norway, December 8th, 2025: Photocure ASA (OSE: PHO), the Bladder Cancer Company, announces the presentation of a health economics abstract from the BRAVO study at the Society of Urologic Oncology 2025 Annual Meeting (SUO) December 2-5, 2025, in Phoenix, AZ. The abstract “COSTS OF CARE AND ONCOLOGIC OUTCOMES ASSOCIATED WITH BLUE LIGHT CYSTOSCOPY IN AN EQUAL ACCESS SETTING: RESULTS FROM THE BRAVO STUDY” compares costs in non-muscle-invasive bladder cancer (NMIBC) care, incurred by white light cystoscopy (WLC) versus blue light cystoscopy (BLC[®]). Results of the real-

New budget impact model study in 4 European countries concludes that BLC use offers a clinically meaningful and economically rational approach to NMIBC management

Press Release – Oslo, Norway, November 19, 2025: Photocure ASA (OSE: PHO), the Bladder Cancer Company, announces the publication of the study “Hexaminolevulinate-enhanced photodynamic diagnosis in the management of non-muscle-invasive bladder cancer (NMIBC): The influence of differing European health care payment systems on the potential financial impact of adoption.” in the Journal of Medical Economics this week. The research objective was to compare the economic implications of blue light cystoscopy (BLC[®]) adoption in line with national guideline recommendations in four European markets.

Photocure ASA: Notification of primary insider transaction

Oslo, Norway, 31 October 2025: Board member Neal Shore has acquired 13,500 shares at a price per share of NOK 55,21. Primary insider notification pursuant to the market abuse regulation article 19 is attached.   For further information, please contact:   Photocure CFO Erik DahlTel: +47 450 55 000Email: ed@photocure.com   About Photocure ASA   Photocure: The Bladder Cancer Company delivers transformative solutions to improve the lives of bladder cancer patients. Our unique technology, making cancer cells glow bright pink, has led to better health outcomes for

Photocure ASA: Results for the third quarter of 2025

Oslo, Norway, 29 October 2025 - Photocure ASA (OSE:PHO) today reported Hexvix®/Cysview® revenues of NOK 134.1 million in the third quarter of 2025 (Q3 2024: NOK 120.1 million), and an EBITDA of NOK 10.2 million (Q3 2024: NOK 5.0 million) for the company. Looking ahead, Photocure expects product revenue growth in the range of 8% to 10% on a constant currency basis (compared to 7 to 11% previously) and an EBITDA improvement in 2025. While the company is not providing a specific EBITDA guidance range, Photocure expects continued operating leverage flow-through in its core commercial business and

Photocure ASA: Invitation to presentation of third quarter 2025 financial results

Oslo, Norway, 23 October 2024: Photocure ASA (Photocure, PHO: OSE) will announce the third quarter 2025 financial results on Wednesday 29 October 2025 at 07:00 CET and will present a live webcast at 14:00 CET the same day.The quarterly report and presentation will be published at 07:00 CET and will be publicly available at www.photocure.com. The investor presentation will be streamed live and hosted by Dan Schneider, CEO and Erik Dahl, CFO. The presentation will be held in English and questions can be submitted throughout the event. The presentation is scheduled to conclude at 14:45 CET.

Photocure and Intelligent Scopes Corporation partner on development of AI for blue light cystoscopy

Press Release – Oslo, Norway, October 15, 2025: Photocure ASA (OSE: PHO), the Bladder Cancer Company, announces that it has entered into a partnership with Intelligent Scopes Corporation (ISC) to develop Artificial Intelligence (AI) software with blue light cystoscopy (BLC[®]). Initial testing shows promising performance results.Photocure and ISC have signed a development agreement on AI software and BLC for the detection of bladder tumors. Photocure is a pioneer in the bladder cancer diagnostics market with its Hexvix[®]/Cysview[®] products, supported by robust clinical evidence and

Photocure ASA - Share option grant

Oslo, Norway, 22 September 2025 - Photocure ASA (the "Company") (OSE: PHO) has granted share options to employees. A total of 348,000 share options, equal to approx. 1.28% of total shares issued in the Company, were granted to employees at an exercise price at NOK 67.39. The exercise price is equal to the weighted average share price 30 trading days before the day of grant with an additional premium of 10% on top of the calculated average price.The options are granted in accordance with Photocure's long term incentive program and the Company's guidelines for remuneration of senior

Asieris: Cevira (APL-1702) NDA Advances to Second Round of Technical Review

Press release – Oslo, Norway, August 4, 2025: Photocure ASA (OSE: PHO), the Bladder Cancer Company, announces that its partner Asieris Pharmaceuticals (SSE: 688176) communicated today that its photodynamic drug-device combination product candidate Cevira (APL-1702), has advanced to the second round of technical review.The company will maintain proactive communication with the Center for Drug Evaluation (CDE) to expedite the New Drug Application (NDA) review process.Cevira (APL-1702) is a photodynamic drug-device combination product in development for the non-surgical treatment of high-

Photocure ASA: Results for the second quarter of 2025

Oslo, Norway, 30 July 2025 - Photocure ASA (OSE:PHO) today reported Hexvix®/Cysview® revenues of NOK 135.6 million in the second quarter of 2025 (Q2 2024: NOK 122.4 million), and an EBITDA of NOK 14.8 million (Q2 2024: NOK 27.8 million, including a milestone payment of NOK 21.6 million) for the company. Photocure expects product revenue growth in the range of 7% to 11% and year-over-year EBITDA improvement in 2025. While the company is not providing a specific EBITDA guidance range, Photocure expects continued operating leverage flow-through in its core commercial business and significant

There are no items matching the current filter
There are no more items matching the current filter
Back to top

Subscribe

Media